Prescient Therapeutics (ASX:PTX), a clinical-stage oncology company developing targeted therapies for cancer treatment, has announced that its Share Purchase Plan (SPP) has raised $6.8 million.
The company stated that the SPP bolsters its cash balance, which will be used to support the advancement of its first-in-class cancer treatment, PTX-100, specifically by funding the current Phase 2 clinical trial and continued clinical development of this targeted therapy.
Prescient CEO James McDonnell said, “On behalf of the Board, I thank Prescient shareholders for their strong support of the SPP, which allows us to accelerate the PTX-100 Phase 2 clinical plan. This is a pivotal moment for the business on its path towards our commercialisation objectives, and I am genuinely excited about the near-term milestones on this journey."
Prescient has also entered into a trading halt for a follow-on placement. Placement shares have the same price as the SPP ($0.04), representing a discount of 11.1 per cent to the last traded price on the ASX (28 July 2025).